Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The goal is to reach the full therapeutic dose without causing unnecessary discomfort
Diabetologia 57 , 295304 (2014)
Of adults receiving combination cagrilintide and semaglutide, 71.4% lost at least 10% of their body weight and 53.6% achieved a 15% or higher weight loss at 32 weeks
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
